Report cover image

Acute Kidney Injury Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146848

Description

Acute kidney injury is a serious condition characterized by a sudden decline in kidney function, which can result from various causes, including trauma, infections, or medications. The condition accounts for around 10-15% of hospital admissions, with prevalence in intensive care unit (ICU) patients rising to over 50%. There is a high unmet clinical need for better therapies to treat acute kidney injury, as current options, such as dialysis, often fail to address the underlying causes effectively. Further, the growing focus on early detection, preventive measures, and novel treatments is likely to support pipeline growth in the coming years, offering hope for improved patient outcomes.

Report Coverage

The Acute Kidney Injury Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into acute kidney injury therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute kidney injury. The acute kidney injury report assessment includes an analysis of over 100 pipeline drugs and 50+ companies. The acute kidney injury pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute kidney injury treatment guidelines to ensure optimal care practices.

The assessment section will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute kidney injury.

Acute Kidney Injury Drug Pipeline Outlook

Acute kidney injury is a sudden loss of kidney function caused by reduced blood flow, direct kidney damage, or urinary obstruction. It often occurs due to severe infections, trauma, or nephrotoxic drugs. Acute kidney injury treatments include supportive care such as fluid management and electrolyte balancing. In severe cases, renal replacement therapy such as dialysis is used.

The acute kidney injury drug pipeline focuses on developing therapies targeting inflammation, oxidative stress, and cellular repair. These advancements aim to address the high unmet need for effective treatments, emphasizing early intervention and organ protection.

Acute Kidney Injury Epidemiology

Acute kidney injury is a significant global health concern, affecting 14.7% to 31.5% of hospitalized patients. In the United States, its incidence has risen by 14% annually since 2001. The ISN 0by25 study reveals that 80% of acute kidney injury in low- and middle-income countries is community-acquired, with dehydration (46%) and hypotension (38%) as leading causes.

Acute Kidney Injury Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of acute kidney injury drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Acute Kidney Injury – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total acute kidney injury clinical trials.

Acute Kidney Injury Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the acute kidney injury pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute kidney injury.

Acute Kidney Injury Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR acute kidney injury report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute kidney injury clinical trials:
  • Hope Biosciences
  • Genentech, Inc.
  • CalciMedica, Inc.
  • Novartis Pharmaceuticals
  • Alexion Pharmaceuticals, Inc.
  • Rediscovery Life Sciences
  • Arch Biopartners Inc.
  • EnnovaBio
  • Baxter Healthcare Corporation
Acute Kidney Injury Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute kidney injury. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute kidney injury drug candidates.

Drug: Ravulizumab

The ARTEMIS study, sponsored by Alexion Pharmaceuticals, Inc., aims to evaluate the efficacy of a single dose of ravulizumab IV compared to a placebo in reducing the risk of AKI-related outcomes (MAKE) in chronic kidney disease patients undergoing non-emergent cardiac surgery with CPB. This Phase 3 trial, with an estimated 736 participants, is expected to conclude by February 2027.

Drug: GDC-8264

The Phase II study, sponsored by Genentech, Inc., aims to evaluate the efficacy and safety of GDC-8264 in preventing cardiac surgery-associated acute kidney injury (AKI) and major adverse kidney events (MAKE90). With an estimated 404 participants, the study is set to begin on January 15, 2025, and is expected to conclude by November 15, 2027.

Reasons To Buy This Report

The Acute Kidney Injury Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for acute kidney injury. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute kidney injury pipeline insights.

Key Questions Answered in the Acute Kidney Injury – Pipeline Insight Report
  • What is the current landscape of acute kidney injury pipeline drugs?
  • Which companies/institutions are developing acute kidney injury emerging drugs?
  • How many phase II drugs are currently present in the acute kidney injury pipeline drugs?
  • Which company is leading the acute kidney injury pipeline development activities?
  • What is the current acute kidney injury therapeutic assessment?
  • What are the opportunities and challenges present in the acute kidney injury drug pipeline landscape?
  • What is the efficacy and safety profile of acute kidney injury pipeline drugs?
  • Which companies/institutions are involved in acute kidney injury collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in acute kidney injury?
Related Reports

Global Acute Kidney Injury Treatment Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Acute Kidney Injury
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Acute Kidney Injury
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Acute Kidney Injury: Epidemiology Snapshot
5.1 Acute Kidney Injury Incidence by Key Markets
5.2 Acute Kidney Injury – Patients Seeking Treatment in Key Markets
6 Acute Kidney Injury: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Acute Kidney Injury: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Acute Kidney Injury, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Acute Kidney Injury Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Acute Kidney Injury Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Prismocitrate 18
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Nitric Oxide, Oxygen
10.2.3 Other Drugs
11 Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: GDC-8264
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: TIN816
11.2.3 Other Drugs
12 Acute Kidney Injury Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: KELI-101
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Acute Kidney Injury Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Acute Kidney Injury, Key Drug Pipeline Companies
14.1 Hope Biosciences
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Genentech, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 CalciMedica, Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Novartis Pharmaceuticals
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Alexion Pharmaceuticals, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Rediscovery Life Sciences
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Arch Biopartners Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 EnnovaBio
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Baxter Healthcare Corporation
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us